{"id":13245,"date":"2010-08-04T10:30:00","date_gmt":"2010-08-04T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/sanofi-aventis-acquisisce-genzyme\/"},"modified":"2010-08-04T10:30:00","modified_gmt":"2010-08-04T08:30:00","slug":"sanofi-aventis-acquisisce-genzyme","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/sanofi-aventis-acquisisce-genzyme\/","title":{"rendered":"Sanofi-Aventis to acquire Genzyme?"},"content":{"rendered":"<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" width=\"251\" height=\"201\" id=\"il_fi\" alt=\"\" src=\"http:\/\/t2.gstatic.com\/images?q=tbn:QimmhTpPivFVEM:http:\/\/greenbuildingelements.com\/files\/images\/genzyme-w.jpg&amp;t=1\" \/>&nbsp;<em> <\/em><\/p>\n<p><em>The <font color=\"#516806\">Genzyme Center<\/font> a Cambridge, Massachusetts<\/em>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<img loading=\"lazy\" decoding=\"async\" width=\"495\" height=\"102\" style=\"width: 188px; height: 40px;\" id=\"rg_hi\" class=\"rg_hi\" alt=\"\" data-width=\"495\" data-height=\"102\" src=\"http:\/\/t2.gstatic.com\/images?q=tbn:ANd9GcTjevInGbvdkbxz-aIWtwX2zJvFJunzsO8qjjGZYWdJ962doU4&amp;t=1&amp;usg=__S6KvDRSrXdzNG9PVv-HFARi4eXs=\" \/><\/p>\n<p style=\"margin: 0cm 0cm 10pt;\" class=\"MsoNormal\"><font face=\"Calibri\"><font size=\"4\">Sanofi-Aventis ha presentato un&rsquo;offerta amichevole alla societ&agrave; americana di biotecnologie Genzyme da 18,4 miliardi di dollari. Sanofi avrebbe proposto 69 dollari per azione. Genzyme non sarebbe per&ograve; disposta ad accettare una proposta sotto gli 80 dollari.<\/p>\n<p><\/font><\/font><\/p>\n<p style=\"margin: 0cm 0cm 10pt;\" class=\"MsoNormal\"><font size=\"3\"><font face=\"Calibri\"><em>ItalyToday <span style=\"\">&nbsp;&nbsp;<\/span>04-08-2010 <span style=\"\">&nbsp;&nbsp;<\/span>pag. 36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/em><\/font><\/font>&nbsp;<img loading=\"lazy\" decoding=\"async\" width=\"543\" height=\"93\" style=\"width: 136px; height: 37px;\" id=\"rg_hi\" class=\"rg_hi\" alt=\"\" data-width=\"543\" data-height=\"93\" src=\"http:\/\/t0.gstatic.com\/images?q=tbn:ANd9GcQsZxtnEPoUuXPI67WzuoGcJbdXNzVuvsfqKwlrJ9F1rCfNrMA&amp;t=1&amp;usg=__oliYyeIR_3VTO7orpFEHiecUSBc=\" \/><\/p>\n<p style=\"margin: 0cm 0cm 10pt;\" class=\"MsoNormal\"><img loading=\"lazy\" decoding=\"async\" width=\"335\" height=\"501\" id=\"il_fi\" src=\"http:\/\/en.sanofi-aventis.com\/binaries\/28-4922-2-Sanofi-aventis%20Group%20head%20office-original_tcm28-22364.jpg\" alt=\"\" \/>&nbsp;<a href=\"http:\/\/en.sanofi-aventis.com\/press\/imglib\/management\/management_committee\/il_28390.asp\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" class=\"media\" title=\"Chris Viehbacher - Chief Executive Officer of sanofi-aventis as of December 1, 2008\" alt=\"Chris Viehbacher - Chief Executive Officer of sanofi-aventis as of December 1, 2008\" src=\"http:\/\/en.sanofi-aventis.com\/binaries\/28-4922-2-Viehbacher-normal_tcm28-28387.jpg\" \/><\/a>&nbsp;<em>Chris Viehbacher &#8211; Chief Executive Officer of Sanofi-Aventis<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>&nbsp; &nbsp; Il Genzyme Center a Cambridge, Massachusetts&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; Sanofi-Aventis ha presentato un&rsquo;offerta amichevole alla societ&agrave; americana di biotecnologie Genzyme da 18,4 miliardi di dollari. Sanofi avrebbe proposto 69 dollari per azione. Genzyme non sarebbe per&ograve; disposta ad accettare una proposta sotto gli 80 dollari. ItaliaOggi &nbsp;&nbsp;04-08-2010 &nbsp;&nbsp;pag. 36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;Chris Viehbacher &#8211; Chief Executive Officer &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13245","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13245"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13245\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}